Rucaparib Camsylate - National Cancer Institute

Rucaparib Camsylate - National Cancer Institute

Rucaparib Camsylate

• 
• 
• 
• 
• 
• 
• 

(roo-KA-puh-rib KAM-suh-layt)

This page contains brief information about rucaparib camsylate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Rubraca

FDA Approved

Yes

FDA Approval for Rucaparib Camsylate

Use in Cancer

Rucaparib camsylate is approved to treat:

• Ovarian cancer that is advanced. It is used in patients whose cancer has certain mutations in the BRCA1 or BRCA2 genes and who have already been treated with at least two other types of chemotherapy.

Rucaparib camsylate is also being studied in the treatment of other types of cancer.

More About Rucaparib Camsylate

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

FDA Approves Rucaparib for BRCA-Positive Ovarian Cancer

Targeted Cancer Therapies

Clinical Trials Accepting Patients

Find Clinical Trials for Rucaparib Camsylate - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.

• Posted: January 3, 2017
• Updated: January 10, 2017